drugset / Trial / NCT02576119

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

NCT02576119 ↗

Phase 1 Terminated 315 enrolled ViiV Healthcare GlaxoSmithKline · collab
RandomizedCrossoverTriple-blindOther

Summary

The purpose of the study is to determine the effect of multiple doses of BMS-955176 on the QT interval corrected with Fridericia's method (QTcF) in healthy subjects.

Timeline

Start
2015-10-19
Primary completion
2016-02-26
Completion
2016-10-14

Outcome

Outcome not reported

Stopped: “This study was terminated early due to neuropsychiatric serious adverse events reported by 2 participants.”

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-955176 Other / unclassified 240 mg Oral
Subject Moxifloxacin Small molecule — —